NDC product
Levalbuterol tartrate HFA inhalation
NDC 0591-2927 · Actavis Pharma, Inc.
Key facts
| Product NDC | 0591-2927 |
|---|---|
| Proprietary name | Levalbuterol tartrate HFA inhalation |
| Nonproprietary name | levalbuterol tartrate |
| Substances | LEVALBUTEROL TARTRATE |
| Dosage form | AEROSOL, METERED |
| Route | ORAL |
| Labeler | Actavis Pharma, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Application number | NDA021730 |
| Pharmacologic classes | Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist [EPC] |
| Marketing start | Oct 3, 2016 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: